Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol

Multiple Sclerosis (MS) is a common cause of neurological disability among young adults and has a high economic burden. Currently there are 18 disease modifying agents for relapsing MS, which were tested in clinical trials versus placebo or an active comparator in a pairwise manner. However, there is currently no consensus on the fundamental principles of treatment approach and initial therapy selection. These factors result in variable use of disease modifying therapies. Here we describe the study protocol for Determining the Effectiveness of earLy Intensive Versus Escalation approaches for the Treatment of Relapsing-remitting Multiple Sclerosis (DELIVER-MS).

Source: Contemporary Clinical Trials - April 18, 2020 Category: Radiology Authors: Daniel Ontaneda, Emma C. Tallantyre, Praneeta C. Raza, Sarah M. Planchon, Kunio Nakamura, Deborah Miller, Carrie Hersh, Mathew Craner, Clare Bale, Burhan Chaudhry, Douglas D. Gunzler, Thomas E. Love, Stephen Gerry, Alasdair Coles, Jeffrey A. Cohen, Nikos Source Type: research